Celgene (CELG) is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug, Otezla.
Despite Celgene's growing product lineup, shares are trading lower following the company's second quarter earnings report. As a result, investors are right to wonder if Celgene's winning streak is coming to an end.
Source: Celgene through June 11, 2014
In the following slideshow, you'll learn which of Celgene's drugs grew fastest and gain insight into whether shares are worth buying.
